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cardiovascular events (MACE), including all-cause death, non-fatal
myocardial infarction and target vessel revascularization (TVR).
RESULTS There were 149 patients with hypothyroidism (13.81%,
including low-T3 syndrome, subclinical hypothyroidism and clinical
hypothyroidism) and 16 patients with subclinical hyperthyroidism.
After adjusting for conventional risk factors (age, gender, smoke,
diabetes mellitus, dyslipidemia, hypertension), fT3 level was signiﬁ-
cantly correlated with log-CKMB (r¼-0.218, p<0.001), log-cTnI (r¼-
0.231, p<0.001), and LVEF (r¼0.463, p<0.001), indicating that the
hypothyroidism is related with myocardial injury and damaged car-
diac function. There are total 86 MACEs during two-year follow-up.
The incidence of MACEs were 14.09% in patients with hypothyroidism
and 6.99% in patients without hypothyroidism, respectively. In
multivariable Cox survival analysis, hypothyroidism is the prognostic
factor for MACE (OR: 3.7; 95%CI: 2.6-6.5) and TVR (OR: 2.3; 95%CI: 1.7-
7.2). As for non-fatal myocardial infarction, hypothyroidism was not a
signiﬁcant predictor (OR: 2.8; 95%CI: 0.6-8.9). Subclinical hyperthy-
roidism did not show any impact on prognosis.CONCLUSIONS Hypothyroidism is associated with cardiac markers
and damaged cardiac function in STEMI. In two-year follow-up, hy-
pothyroidism is a predictor for MACE and TVR in STEMI patients
treated with primary PCI. Further studies on treatment of MI with
thyroid dysfunction are needed
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BACKGROUND Triple antiplatelet therapy (TAT) including cilostazol
has showed beneﬁcial effect on mortality with safety in patients with
ST elevation myocardial infarction (STEMI) compared to dual anti-
platelet therapy (DAT). However, considering the bleeding risk in
elderly patients, it is not clear whether these beneﬁcial effects also
show or not. Thus, we compared the effect of triple antiplatelet
therapy (TAT) with DAT in elderly patients with STEMI underwent
primary percutaneous coronary intervention (PCI).
METHODS From 2007 to 2014, a total of 1401 consecutive patients
(79.6% male) with STEMI underwent primary PCI were analyzed
retrospectively. Patients were divided into two groups according to
their age (group 1: < 75 years old, group 2: 75 years old). Primary
endpoint was all-cause mortality during follow-up period.
RESULTS Of the 1401 patients, there were 1160 (82.8%, mean age
56.310.4) patients in group 1, 241 (17.2%, 80.34.5) patients in group
2. Prevalence of DM, hypertension and multi-vessel disease were
more common in group 2. In group 1, there were 235 patients (20.3%)
with TAT and 29 patients (12.0%) with TAT in group 2. Over a mean
follow-up period of 2.11.5 years, there were 90 in deaths (4.3% in
group 1 vs. 28.3% in group 2). Kaplan-Meier survival analysis revealed
that TAT was associated with lower mortality rate in group 1 (log rank
p-value¼0.023). Whereas, this beneﬁcial effect was not noted in group
2 (log rank p-value¼0.958).
CONCLUSIONS On the contrary to young patients (< 75 years old),
TAT was not associated survival beneﬁt compared to DAT in elderly
patients (75 years old) with STEMI underwent primary PCI.
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